Form 4: United Therapeutics Director Sells Shares Under 10b5-1 Plan

Judy D. Olian, a director at United Therapeutics Corp, sold 200 shares of common stock for $535.44 per share under a pre-arranged 10b5-1 plan.

Summary

• Judy D. Olian, a Director of United Therapeutics Corp (UTHR), reported a transaction.
• The transaction involved the sale of 200 shares of common stock.
• The sale occurred on March 16, 2026, at a price of $535.44 per share.
• This sale was executed pursuant to a pre-arranged Rule 10b5-1 plan, which was entered into on November 24, 2025.
• Following this transaction, Judy D. Olian beneficially owns 4,445 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral. A director's sale of shares under a pre-arranged 10b5-1 plan is a routine event for personal financial management and typically does not convey a strong positive or negative signal about the company's prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a pre-arranged 10b5-1 plan, are a common practice for corporate directors and executives for personal financial planning and diversification. Such sales do not necessarily indicate a change in the company's fundamental outlook, especially when pre-scheduled, and are generally viewed as routine disclosures in the broader pharmaceutical and biotechnology industry.

Stakeholder Impact

• Shareholders may note the director's reduced direct ownership stake, though the pre-arranged nature of the sale under a 10b5-1 plan suggests it is for personal financial planning rather than a reaction to new company-specific information.

Key Dates

Recommendation

The filing reports a routine insider sale under a 10b5-1 plan, which is a common practice for personal financial planning and diversification. It does not provide new information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the transaction itself is neutral.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Sale, Director, Judy D. Olian, 10b5-1 Plan